Cargando…
Experimental α-particle radioimmunotherapy of breast cancer using (227)Th-labeled p-benzyl-DOTA-trastuzumab
BACKGROUND: The aim of the present study was to explore the biodistribution, normal tissue toxicity, and therapeutic efficacy of the internalizing low-dose rate alpha-particle-emitting radioimmunoconjugate (227)Th-trastuzumab in mice with HER2-expressing breast cancer xenografts. METHODS: Biodistrib...
Autores principales: | Abbas, Nasir, Heyerdahl, Helen, Bruland, Øyvind S, Borrebæk, Jørgen, Nesland, Jahn, Dahle, Jostein |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3250964/ https://www.ncbi.nlm.nih.gov/pubmed/22214432 http://dx.doi.org/10.1186/2191-219X-1-18 |
Ejemplares similares
-
Fractionated Therapy of HER2-Expressing Breast and Ovarian Cancer Xenografts in Mice with Targeted Alpha Emitting (227)Th-DOTA-p-benzyl-trastuzumab
por: Heyerdahl, Helen, et al.
Publicado: (2012) -
Evaluation of CD146 as Target for Radioimmunotherapy against Osteosarcoma
por: Westrøm, Sara, et al.
Publicado: (2016) -
(177)Lu-DOTA-HH1, a Novel Anti-CD37 Radio-Immunoconjugate: A Study of Toxicity in Nude Mice
por: Repetto-Llamazares, Ada H. V., et al.
Publicado: (2014) -
Development of DOTA-Rituximab to be Labeled with (90)Y for Radioimmunotherapy of B-cell Non-Hodgkin Lymphoma
por: Johari doha, Fariba, et al.
Publicado: (2017) -
Evaluation of Candidate Theranostics for (227)Th/(89)Zr Paired Radioimmunotherapy of Lymphoma
por: Abou, Diane S., et al.
Publicado: (2023)